These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 16365478)

  • 1. Tumor necrosis factor-alpha inhibitor therapy in erosive polyarthritis secondary to systemic sclerosis.
    Bosello S; De Santis M; Tolusso B; Zoli A; Ferraccioli G
    Ann Intern Med; 2005 Dec; 143(12):918-20. PubMed ID: 16365478
    [No Abstract]   [Full Text] [Related]  

  • 2. A case of arthritis and vasculitis associated with the refractory anemia with excess of blasts syndrome resistant to glucocorticoid treatment that responded favorably to TNF-alpha blockade.
    Pipitone N; Masini L; Salvarani C
    Clin Exp Rheumatol; 2006; 24(2 Suppl 41):S31-4. PubMed ID: 16859593
    [No Abstract]   [Full Text] [Related]  

  • 3. [Tumor necrosis factor a inhibitors in treatment of Crohn's disease].
    Vermel' AE
    Klin Med (Mosk); 2005; 83(11):13-7. PubMed ID: 16404932
    [No Abstract]   [Full Text] [Related]  

  • 4. Psoriasis: TNF-alpha inhibitors and beyond.
    Kincaid L
    Drug Discov Today; 2005 Jul; 10(13):884-6. PubMed ID: 15993806
    [No Abstract]   [Full Text] [Related]  

  • 5. Australian data do not support current Pharmaceutical Benefits Scheme criteria for use of tumour necrosis factor-alpha inhibitors in ankylosing spondylitis.
    Schachna L; Brown MA
    Intern Med J; 2006 Nov; 36(11):755-6. PubMed ID: 17040370
    [No Abstract]   [Full Text] [Related]  

  • 6. Update of TNF-alpha antagonists and cardiovascular disease in rheumatoid arthritis.
    del Rincón I; Escalante A
    Curr Rheumatol Rep; 2005 Oct; 7(5):395-9. PubMed ID: 16174491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy.
    Mäki-Petäjä KM; Hall FC; Booth AD; Wallace SM; Yasmin ; Bearcroft PW; Harish S; Furlong A; McEniery CM; Brown J; Wilkinson IB
    Circulation; 2006 Sep; 114(11):1185-92. PubMed ID: 16952987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of sarcoidosis during etanercept therapy.
    González-López MA; Blanco R; González-Vela MC; Fernández-Llaca H; Rodríguez-Valverde V
    Arthritis Rheum; 2006 Oct; 55(5):817-20. PubMed ID: 17013853
    [No Abstract]   [Full Text] [Related]  

  • 9. Inhibition of established collagen-induced arthritis with a tumour necrosis factor-alpha inhibitor expressed from a self-contained doxycycline regulated plasmid.
    Gould DJ; Bright C; Chernajovsky Y
    Arthritis Res Ther; 2004; 6(2):R103-13. PubMed ID: 15059273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of acrodermatitis continua of Hallopeau by the tumour necrosis factor-alpha inhibitor infliximab (Remicade).
    Mang R; Ruzicka T; Stege H
    Br J Dermatol; 2004 Feb; 150(2):379-80. PubMed ID: 14996123
    [No Abstract]   [Full Text] [Related]  

  • 11. Tumor necrosis factor alpha inhibitors and methotrexate: implications for deployed personnel.
    Martin JJ
    Aviat Space Environ Med; 2005 Dec; 76(12):1162-6. PubMed ID: 16370267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subsidised access to TNF-alpha inhibitors: is the rationale for exclusion of rheumatoid-factor-negative patients defensible?
    Mann EL
    Med J Aust; 2005 Jan; 182(1):47-8. PubMed ID: 15651955
    [No Abstract]   [Full Text] [Related]  

  • 13. Is there a rationale for combined TNF and IL-1 blocking in arthritis?
    van den Berg WB
    Clin Exp Rheumatol; 2002; 20(5 Suppl 27):S21-5. PubMed ID: 14989425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Induction of remission with TNF-alpha inhibitor in Crohn disease. An analysis of a systematic Cochrane review].
    Nielsen OH; Madsen JR
    Ugeskr Laeger; 2004 Nov; 166(47):4248-51. PubMed ID: 15587355
    [No Abstract]   [Full Text] [Related]  

  • 15. Reconstructing the pyramid in rheumatoid arthritis. An urgent need.
    Ferraccioli GF; Valentini G; Valesini G; Bombardieri S
    Clin Exp Rheumatol; 2001; 19(6):621-4. PubMed ID: 11791629
    [No Abstract]   [Full Text] [Related]  

  • 16. New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists.
    Greig NH; Mattson MP; Perry T; Chan SL; Giordano T; Sambamurti K; Rogers JT; Ovadia H; Lahiri DK
    Ann N Y Acad Sci; 2004 Dec; 1035():290-315. PubMed ID: 15681814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulators.
    Reuman PD
    Pediatr Infect Dis J; 2001 Oct; 20(10):995-6. PubMed ID: 11642636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of refractory rheumatoid arthritis-associated leg ulcerations with adalimumab.
    Hirche D; Rubbert A; Lunau L; Krieg T; Eming SA
    Br J Dermatol; 2005 May; 152(5):1062-4. PubMed ID: 15888173
    [No Abstract]   [Full Text] [Related]  

  • 19. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment.
    Ziolkowska M; Kurowska M; Radzikowska A; Luszczykiewicz G; Wiland P; Dziewczopolski W; Filipowicz-Sosnowska A; Pazdur J; Szechinski J; Kowalczewski J; Rell-Bakalarska M; Maslinski W
    Arthritis Rheum; 2002 Jul; 46(7):1744-53. PubMed ID: 12124857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Soluble TNF-alpha receptors].
    Jabłońska E
    Postepy Hig Med Dosw; 1997; 51(5):567-75. PubMed ID: 9489455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.